A Phase III Trial of External Beam of Radiotherapy +/- Total Androgen Suppression for High Risk Clinically Organ-Confined Prostate Cancer

Trial Profile

A Phase III Trial of External Beam of Radiotherapy +/- Total Androgen Suppression for High Risk Clinically Organ-Confined Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Flutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary) ; Antiandrogens; Gonadotropin releasing hormone stimulants
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Apr 2017 to 1 Sep 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top